利培酮与氟派啶醇治疗Tourette综合征疗效的对照研究

A compared study of treating Tourette＇s syndrome with Risperidone

目的：探讨利培酮单一治疗Tourette综合征（TS）的疗效和安全性。方法：将58例TS患者按病历编号分为研究组（32例）和对照组（16例）。研究组予利培酮（0.5-3mg/d）治疗;对照组予氟哌啶醇（1.5-6mg/d）,共治疗24周。采用耶鲁抽动症整体严重度量表（YGTSS）、治疗中需处理的不良反应症状量表（TESS）于治疗前及治疗第8、24周末对两组进行评估。结果：①治疗第8周末研究组有效率72%,高于对照组（38%;Z=-3.284,P=0.001）。研究组YGTSS总分[（28.06±14.45）分]低于对照组[（40.00±20.90）分,P〈0.05];减分率[（48.10±22.80）%]高于对照组[（33.17±31.90）%,但P〉0.05]。治疗第24周末,研究组有效率为81%,高于对照组（56%,Z=-4.808,P〈0.001）。研究组YGTSS总分[（24.96±16.28）分]低于对照组[（36.50±21.08）分,P〈0.05];减分率[（52.90±24.49）%]高于对照组[（34.63±32.58）%,P〈0.05]。②第8周末研究组TESS分[（2.69±3.02）分]低于对照组[（6.25±4.06）分,P〈0.01]。第24周末研究组TESS分[（1.69±1.79）分]低于对照组[（2.69±3.02）分,P〈0.01]。结论：利培酮有效改善TS的运动、发生抽动和综合损伤效应,副作用相对较轻。

Objective： The aim of this study was to determine the efficacy and safey of risperidone in treating Tourette＇s syndrome（TS）. Methods： An open - labeled control study was carried out. Fifth - eigth patients met the DSM - IV criteria for TS were involved in the study. Subjects were given 24 - week risperidone （0.5 ~ 3rag/d;35 eases）or haloperidol medication（1.5 - 6rag/d; 18 cases）. The efficacy was assessed with the Yale Global Tic Severity Scale（YGTSS） and the safety with the Treatment Emergent Symptom Scale（TESS） at baseline and at the end of 8th,24th week of the study. Results： Foyty - eight subjects completed the study, with 3 in risperidone group and 7 in haloperidol group dropped out. The efficacy in the risperidone group was significantly better than that in control group, with rcspone rates of 72% and 38% respectively after 8 - week treatment,and the YGTSS total score was significantly lower in risperidone group compared to haloperidol group（ P 〈 0.05）. After 24 - week treatment, there were more higher respone rate（81% vs.56%）,lower YGTSS score in risperidonc group than in haloperidol both at the end of 8- week and 24- week treatment （ P 〈 0.01 ）. Conlusion： It is effective and safe of risperidone in treating Tourette＇s syndrome.